Precision BioSciences, Inc

Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform. The company develops in vivo therapies for genetic and infectious diseases and also licenses ARCUS-related intellectual property to collaborators and other biotechnology companies.

−147,9 %

−133,4 %

−50,1 %

13.32

13.32

— Precision BioSciences, Inc
%
ARCUS platform and therapeutic programs85% Development of proprietary genome editing tools and therapeutic candidates for human disease.
Licensing and collaboration revenue15% Upfront payments, milestones, and royalties from partners using ARCUS-related IP.

Precision BioSciences sells primarily to pharmaceutical and biotechnology partners through licensing and collaboration...

  • Biotechnology and pharmaceutical collaboratorsprimary

    License ARCUS IP or partner on preclinical programs in exchange for upfront fees, milestones, and royalties.

  • Future therapeutic end userssecondary

    Patients with genetic or infectious diseases who would receive approved ARCUS-based therapies.

  • Research and development partnerssecondary

    Companies and institutions that use ARCUS in discovery, preclinical, or translational work.

Precision BioSciences is headquartered in the United States and conducts its research, development, and corporate...

  • •Headquartered in the United States
  • •Core R&D and corporate operations are U.S.-based
  • •Collaborations can extend to global biopharma partners
  • •Future clinical development will depend on U.S. and foreign regulators
  • •No country-level revenue disclosure was provided

The company’s strategy is to advance ARCUS-based in vivo therapies while using partnerships and licensing to monetize...

01
Advance ARCUS therapeutic pipelinemedium-term

Internal programs are the main path to long-term value creation and future product revenue.

02
Monetize platform through licensing and collaborationsshort-term

Partner deals can generate non-product revenue and external validation of ARCUS technology.

03
Strengthen IP and development capabilitiesmedium-term

Genome editing is highly IP-intensive and requires strong preclinical and manufacturing execution.

Precision BioSciences faces the typical risks of a clinical-stage gene editing company: uncertain clinical outcomes,...

high

Clinical development failure

Therapeutic candidates are still in development and may not show safety or efficacy.

Scope
In vivo gene editing programs
Materiality
high
high

Regulatory approval risk

Gene editing products face stringent FDA and foreign review, with possible restrictions or denial.

Scope
Future BLA or foreign marketing applications
Materiality
high
high

Intellectual property and license risk

The business depends on patents and license agreements that can expire or be challenged.

Scope
ARCUS platform and Cellectis-related license terms
Materiality
high
high

Financing risk

The company has not generated product sales and relies on external capital to fund R&D.

Scope
Equity, debt, and collaboration financing
Materiality
high
medium

Partner concentration and collaboration risk

A meaningful part of revenue comes from collaboration accounting and partner milestones.

Scope
Novartis, Caribou, TG Therapeutics, Imugene
Materiality
medium
medium

Cybersecurity and third-party execution risk

R&D, manufacturing, and collaborator data flows depend on external systems and vendors.

Scope
CROs, CMOs, collaborators, internal systems
Materiality
medium
Revenue recognition for collaboration and license agreements
Can cause large fluctuations unrelated to current-period cash receipts
Deferred revenue roll-off
Major driver of year-to-year revenue variability
Stock-based compensation
Affects operating loss and comparability across periods
Lease accounting and R&D commitments
Affects balance sheet liabilities and operating expense timing

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

PRECIGEN, INC.

PGEN · Pharmaceutical Preparations

Precise Biometrics

PREC.ST · Technology

Praxis Precision Medicines, Inc.

PRAX · Pharmaceutical Preparations

EXACT SCIENCES CORP

EXAS · Services-Medical Laboratories

MBX Biosciences, Inc.

MBX · Pharmaceutical Preparations

: 29/04/2026